S Jeha

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 103:784-9. 2004
  2. ncbi request reprint Risk-adapted treatment of pediatric acute lymphoblastic leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 23:973-90, v. 2009
  3. pmc Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA
    J Clin Oncol 27:4392-7. 2009
  4. doi request reprint New therapeutic strategies in acute lymphoblastic leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Semin Hematol 46:76-88. 2009
  5. ncbi request reprint Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial
    S Jeha
    St Jude Children s Research Hospital, 3432 N Lauderdale, Memphis, TN 38105, USA
    Leukemia 19:34-8. 2005
  6. ncbi request reprint Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome
    Sima Jeha
    St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Contrib Nephrol 147:69-79. 2005
  7. ncbi request reprint Clofarabine for the treatment of acute lymphoblastic leukemia
    Sima Jeha
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Expert Rev Anticancer Ther 7:113-8. 2007
  8. ncbi request reprint Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 24:1917-23. 2006
  9. pmc Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 108:3302-4. 2006
  10. ncbi request reprint Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 23:1137-44, viii. 2009

Detail Information

Publications51

  1. ncbi request reprint Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 103:784-9. 2004
    ..Clofarabine is well tolerated and shows significant antileukemic activity in heavily pretreated children. Multicenter phase 2 trials in pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are ongoing...
  2. ncbi request reprint Risk-adapted treatment of pediatric acute lymphoblastic leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 23:973-90, v. 2009
    ..Recent advances in genome-wide screening techniques, pharmacogenomic studies, and development of molecular therapeutics are ushering in an era of more refined personalized therapy...
  3. pmc Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA
    J Clin Oncol 27:4392-7. 2009
    ..To determine the efficacy and safety of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia (AML)...
  4. doi request reprint New therapeutic strategies in acute lymphoblastic leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Semin Hematol 46:76-88. 2009
    ..Some have already been adopted into standard regimens, while others remain in early stages of development. This review summarizes the current status of these novel therapies as they get integrated into ALL regimens...
  5. ncbi request reprint Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial
    S Jeha
    St Jude Children s Research Hospital, 3432 N Lauderdale, Memphis, TN 38105, USA
    Leukemia 19:34-8. 2005
    ..These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia...
  6. ncbi request reprint Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome
    Sima Jeha
    St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Contrib Nephrol 147:69-79. 2005
    ..A recombinant form of urate oxidase, rasburicase, is now available. In this chapter we will present an overview of rasburicase development and discuss the impact of rasburicase in the prevention and management of TLS...
  7. ncbi request reprint Clofarabine for the treatment of acute lymphoblastic leukemia
    Sima Jeha
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Expert Rev Anticancer Ther 7:113-8. 2007
    ..Ongoing studies are exploring the benefit of clofarabine combinations in less heavily pretreated patients and the use of different dose schedules in a variety of hematological malignancies...
  8. ncbi request reprint Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 24:1917-23. 2006
    ..To evaluate the efficacy and safety of clofarabine, a novel deoxyadenosine analog, in pediatric patients with refractory or relapsed acute lymphoblastic leukemia (ALL)...
  9. pmc Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 108:3302-4. 2006
    ..9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens...
  10. ncbi request reprint Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 23:1137-44, viii. 2009
    ..Ongoing trials are studying the benefits of clofarabine combinations in less heavily pretreated patients, and the use of different dose schedules in a variety of hematologic malignancies...
  11. pmc Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
    C H Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 24:371-82. 2010
    ..The next main challenge is to further increase cure rates while improving quality of life for all patients...
  12. pmc Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
    S Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1406-9. 2009
    ..These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse...
  13. pmc ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy
    D Bhojwani
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 26:265-70. 2012
    ....
  14. pmc Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity
    S H Chen
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 88:191-6. 2010
    ..05) in both cohorts. Chromosome 5q33 has previously been associated with asthma and atopy. These data contribute to the growing body of evidence that there is an inherited component to predisposition to drug allergy...
  15. ncbi request reprint Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:1399-403. 2005
    ..In conclusion, the prognostic impact of overt testicular disease has diminished. Irradiation appears to provide no survival advantage to this patient population...
  16. pmc Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia
    J R Roberson
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:245-50. 2009
    ..Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome. Occurrence of hyperglycemia does not warrant alteration of the antileukemic regimen...
  17. pmc Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase
    C A Fernandez
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA
    Cancer Chemother Pharmacol 73:1307-13. 2014
    ..Here, we report successful challenges using native Escherichia coli asparaginase after previous hypersensitivity reactions to both PEGylated E. coli asparaginase and Erwinia asparaginase...
  18. pmc Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Blood 108:3997-4002. 2006
    ..Further, the systemic clearance of methotrexate, teniposide, etoposide, and cytarabine did not differ with BMI (P > .3). We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL...
  19. ncbi request reprint Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions
    Bassem I Razzouk
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, and Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer 106:2495-502. 2006
    ..The prognostic significance of age among pediatric patients with acute myeloid leukemia (AML) was investigated...
  20. ncbi request reprint Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7936-41. 2005
    ..Our goal was to use the information to further refine therapy and advance cure rates...
  21. ncbi request reprint New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA
    Nat Rev Drug Discov 6:149-65. 2007
    ....
  22. pmc Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Cancer 116:227-32. 2010
    ....
  23. ncbi request reprint Clofarabine
    Ching Hon Pui
    Leukemia Lymphoma Division, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Nat Rev Drug Discov . 2005
    ..It is the first new drug for paediatric leukaemia to be approved in more than a decade, and the only one to receive approval for paediatric use before adult use...
  24. pmc Treating childhood acute lymphoblastic leukemia without cranial irradiation
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:2730-41. 2009
    ..Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse...
  25. ncbi request reprint Drug interactions in childhood cancer
    Cyrine Haidar
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN, USA
    Lancet Oncol 12:92-9. 2011
    ..Because of the constant release of new drugs, health-care providers need to check the most recent references before making recommendations about drug interactions...
  26. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011
    ..We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group...
  27. ncbi request reprint Clofarabine
    Ching Hon Pui
    Leukemia Lymphoma Division, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105 2794, USA
    Nat Rev Drug Discov 4:369-70. 2005
  28. doi request reprint Clofarabine in refractory Langerhans cell histiocytosis
    Carlos Rodriguez-Galindo
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 51:703-6. 2008
    ..In this report we describe significant single agent activity of clofarabine in disseminated LCH refractory to salvage regimens, including cladribine...
  29. pmc Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia
    C Liu
    Department of Pharmaceutical Sciences, Memphis, TN, USA
    Leukemia 26:2303-9. 2012
    ..83; 95% confidence interval, 0.78-0.89; P=0.007). Antibodies were related to clinical allergy and to low systemic exposure to asparaginase, leading to lower risk of some adverse effects of therapy...
  30. ncbi request reprint Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 18:1581-6. 2004
    ..0+/-9.6% for those with late relapse and 20.0+/-8.0% for those with early relapse. We conclude that low-dose etoposide administered orally has a cytoreductive effect in relapsed ALL...
  31. pmc Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings
    Fulvia Brugnoletti
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 52:293-5. 2009
    ..Resolution of diffusion abnormalities did not preclude further toxicity and a large lesion could cause persisting symptoms...
  32. ncbi request reprint Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
    Hagop M Kantarjian
    Departments of Leukemia, Experimental Therapeutics, and Breast and Head and Neck, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1167-73. 2003
    ..To define the maximum-tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of clofarabine, given as a 1-hour infusion daily for 5 days, in patients with solid tumors and with acute leukemia...
  33. ncbi request reprint Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia
    Peter G Steinherz
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Hematol Oncol 29:656-8. 2007
    ..The remissions were sustained with repeated cycles of monotherapy for 47, 59, and 64 weeks, respectively...
  34. ncbi request reprint The biology and therapy of adult acute lymphoblastic leukemia
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1337-54. 2003
    ..This has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities...
  35. ncbi request reprint A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:310-4. 2003
    ..Rituximab is used to primarily deplete normal B cells from HD lesions...
  36. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  37. ncbi request reprint Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels
    Sima Jeha
    Department of Pediatrics, University of Texas, M D Anderson Cancer Center, P O Box 072, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 26:399-402. 2002
    ..Unlike in adults, VEGF and VEGF-R2 levels in pediatric AML patients did not correlate with survival. This data suggest that the role of VEGF and its receptor VEGF-R2 in pediatrics AML may be different from that in adult AML...
  38. ncbi request reprint Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:3794-800. 2003
    ..The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy...
  39. ncbi request reprint Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
    ....
  40. ncbi request reprint Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:813-22. 2006
    ..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
  41. ncbi request reprint The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 103:1985-95. 2005
    ..Novel schedules are being explored in lymphoproliferative disorders and solid tumors. Clofarabine is a new nucleoside analog with considerable activity and an acceptable safety profile in acute leukemias...
  42. ncbi request reprint Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    Hagop Kantarjian
    Department of Leukemia, Anderson Cancer Center, Houston, TX, USA
    Blood 102:2379-86. 2003
    ..03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance...
  43. ncbi request reprint Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
    Hagop M Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 101:97-100. 2003
    ..001). Competitive quantitative polymerase chain reaction (QPCR) studies at 9 months showed a median QPCR value (ratio of BCR-ABL/ABL transcripts x 100) of 0.59% overall and of 0.24% (range, 0.001%-29.5%) for complete cytogenetic response...
  44. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  45. ncbi request reprint Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2212-7. 2003
    ..The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown...
  46. ncbi request reprint Clofarabine: past, present, and future
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Andreson Cancer Center, Houston, Texas 77030, USA
    Leuk Lymphoma 48:1922-30. 2007
    ..Ongoing and future studies will examine the use of clofarabine in elderly patients with AML for whom standard regimens are too toxic, and in MDS intravenous and oral forms of the drug...
  47. ncbi request reprint A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2908-17. 2004
    ..As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS)...
  48. ncbi request reprint Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2788-801. 2004
    ..The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) program, with a median follow-up time of 63 months...
  49. ncbi request reprint Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia
    Peter L Bonate
    ILEX Products, 4545 Horizon Hill Boulevard, San Antonio, TX 78229, USA
    J Clin Pharmacol 44:1309-22. 2004
    ..The results confirm that clofarabine should continue being dosed on a per-squaremeter or per-body-weight basis...
  50. ncbi request reprint Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia
    Andreia A Canalli
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 29:881-5. 2005
    ..003). These results indicate that differences in DNA methylation of specific molecular pathways may contribute to the prognostic differences known to occur between pediatric and adult patients with ALL...
  51. ncbi request reprint Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:1492-9. 2002
    ....